MedTrace Logo

Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With Myopia

NCT07790640 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 351

Last updated 2026-09-01

No results posted yet for this study

Summary

This study was to evaluate the superiority of the myopia progression control effect in the treatment group compared with the control group, evaluated by the change in spherical equivalent (SE) after 12 months of administration of the investigational product.

Conditions

  • Myopia

Interventions

DRUG

CTO0308

Ophthalmic solution, one drop in each eye, once daily

DRUG

Vehicle (Placebo solution)

Vehicle, one drop in each eye, once daily

Sponsors & Collaborators

  • Taejoon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-11
Primary Completion
2027-04-01
Completion
2027-09-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07790640 on ClinicalTrials.gov